GenSci Showcases Innovation at CPHI Korea 2026

SEOUL, Korea — CPHI Korea 2026, one of Asia-Pacific's most influential pharmaceutical industry events, was successfully held at COEX Seoul from August 25 to 27, 2026. As a key member of the China Jilin Pavilion, Changchun Genescience Pharmaceutical Co., Ltd. (GenSci) showcased its comprehensive portfolio across three core therapeutic areas and demonstrating its innovation strength and global strategy in biopharmaceuticals.

Three Core Therapeutic Areas Highlighting Innovation

At the exhibition, GenSci presented its product pipeline and technological advantages in three major therapeutic areas:

Women's Health — China's first recombinant human Follitropin (FSH) spans three generations of products  with dosage strengths ranging from 75IU to 900IU, and is equipped with a custom 0.25mm ultra-fine needle, offering greater flexibility in treatment. Moreover, EU registration of Progesterone Injection is progressing steadily, with both vial and PFS formulations available to meet diverse market needs.

Growth Hormone — The First-In-Class PEGylated long-acting recombinant human growth hormone (PEG-GH) has evolved through three generations of technology development, from powder to liquid to long-acting, reducing injection frequency to once a week and and significantly improving patient adherence.

Gout Treatment — Firsekibart, an innovative monoclonal antibody, is designed with a twice-yearly dosing regimen, reducing the burden of frequent injections while  bringing a new long-term targeted treatment option to patients.

Global Client Engagement and Fruitful Cooperation

Over the three-day exhibition, GenSci welcomed the existing and prospective clients from four key regions, including APAC, CIS, GCC, and LATAM. Moreover, the team also met with key Korean clients as scheduled, with discussions focusing on regulatory pathways, technology transfer, and regional exclusive distribution. Multiple cooperation intentions were reached, laying a solid foundation for GenSci's further expansion in the Korean and global markets.

Deepening Global Presence for a Healthier Future

GenSci's successful participation in CPHI Korea 2026 has further strengthened its presence  in the Korean and Asia-Pacific markets and expanded  its global partner network. As a leading Chinese biopharmaceutical enterprise, GenSci remains committed to innovation-driven development and providing high-quality biopharmaceutical products and services to patients worldwide.

Next stop: CPHI Worldwide 2026 in Milan.

GenSci looks forward to partnering with more global collaborators to advance pharmaceutical health for all.